GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Retained Earnings

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Retained Earnings : $-11.67 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Frazier Lifesciences Acquisition's retained earnings for the quarter that ended in Sep. 2022 was $-11.67 Mil.

Frazier Lifesciences Acquisition's quarterly retained earnings declined from Mar. 2022 ($-4.98 Mil) to Jun. 2022 ($-6.18 Mil) and declined from Jun. 2022 ($-6.18 Mil) to Sep. 2022 ($-11.67 Mil).

Frazier Lifesciences Acquisition's annual retained earnings increased from . 20 ($0.00 Mil) to Dec. 2020 ($-10.54 Mil) and increased from Dec. 2020 ($-10.54 Mil) to Dec. 2021 ($-6.36 Mil).


Frazier Lifesciences Acquisition Retained Earnings Historical Data

The historical data trend for Frazier Lifesciences Acquisition's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition Retained Earnings Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
Retained Earnings
-10.54 -6.36

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Retained Earnings Get a 7-Day Free Trial Premium Member Only -7.29 -6.36 -4.98 -6.18 -11.67

Frazier Lifesciences Acquisition Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Frazier Lifesciences Acquisition  (NAS:FLAC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830